Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Escalated Dosing Schedules of CC-486 Effective for Patients Experiencing First AML Low Blast Count Relapse

2020 Year in Review - AML - Leukemia

This study evaluated clinical outcomes for patients with acute myeloid leukemia (AML) in the QUAZAR AML-001 trial who relapsed with 5% to 15% blasts on-study, who then received escalated 21-day dosing of the study drug. QUAZAR AML-001 was an international, randomized, double-blind phase 3 trial of the oral azacitidine formulation CC-486. Eligible patients were aged ≥55 years, with intermediate- or poor-risk cytogenetics and Eastern Cooperative Oncology Group performance status scores ≤3, and had achieved their first complete remission (CR1) or CR1 with incomplete blood count recovery (CR1i) after induction chemotherapy ± consolidation. Patients were randomized 1:1 to receive post-CR1 maintenance therapy with CC-486 300 mg or placebo, once daily on days 1 to 14 of repeated 28-day treatment cycles within 4 months of achieving CR1/CR1i. Disease status was centrally assessed every 3 cycles. Patients who exhibited signs of relapse based on hematology parameters at routine clinic visits could have a bone marrow test to confirm AML relapse. At the investigator’s discretion, patients who developed low blast counts (5%-15%) in peripheral blood or bone marrow could receive CC-486 for 21 days/cycle. Patients could continue on treatment until follow-up blast counts exceeded 15%, unacceptable toxicity, or they received an allogeneic hematopoietic stem-cell transplant.

A total of 472 patients were randomized to CC-486 (N = 238) or placebo (N = 234) maintenance post-CR1/CR1i. Ninety-one patients (CC-486, N = 51 [21%]; placebo, N = 40 [17%]) experienced early AML relapse with 5% to 15% blasts, and were assigned to receive the study drug on a 21-day/cycle dosing schedule. The median time to dose escalation was 9.2 months (range, 1.0-52.7 months) for CC-486 and 6.0 months (range, 0.5-19.3 months) for placebo. The median number of 21-day dosing cycles was 2.0 for both arms (range: CC-486, 1-45; placebo, 1-16); however, proportionally more patients in the CC-486 (43%) arm received >3 escalated dosing cycles than in the placebo (18%) arm. Of the 78 evaluable patients with ≥5% blasts in bone marrow on or before day 1 of 21-day dosing, 23% of patients in the CC-486 arm and 11% of patients in the placebo arm regained CR1/CR1i while receiving an escalated dosing regimen. The median overall survival from the time of randomization among all patients who received escalated dosing schedules was 22.8 months in the CC-486 arm versus 14.6 months in the placebo arm (hazard ratio, 0.66; 95% confidence interval, 0.42-1.04; P = .07).

During 21-day dosing, the most common adverse events first reported were febrile neutropenia (CC-486, 24%; placebo, 3%), thrombocytopenia (22% vs 23%), anemia (22% vs 20%), and neutropenia (20% vs 10%). The proportion of patients in each arm who first experienced a grade 3/4 adverse event while receiving escalated dosing was similar (CC-486, 31%; placebo, 35%). In the CC-486 arm, 4 patients discontinued due to an adverse event during treatment, while in the placebo arm, 1 patient discontinued; no event was considered related to the study drug. As assessed by the Functional Assessment of Chronic Illness Therapy-Fatigue and EuroQol-5 Dimension-3 Level, CC-486 dose escalation did not negatively impact patient health-related quality of life when compared with placebo.

An escalated 21-day CC-486 dosing regimen was well-tolerated and restored remission in approximately 25% of patients. Disease relapse may have contributed to the hematologic adverse events first reported during escalated dosing in both treatment arms. For patients who experience AML relapse with ≤15% blasts while receiving post-CR1/CR1i maintenance with CC-486, a 21-day dosing schedule of this agent may be a viable salvage option.


Dohner H, Wei AH, Montesinos P, et al. Escalated Dosing Schedules of CC-486 Are Effective and Well Tolerated for Patients Experiencing First Acute Myeloid Leukemia (AML) Relapse: Results from the Phase III QUAZAR AML-001 Maintenance Trial. Presented at: 62nd American Society of Hematology Annual Meeting & Exposition, December 5-8, 2020. Abstract 111.

Related Items
Tibsovo Received a New Indication, in Combination with Azacitidine, for Newly Diagnosed Patients with AML and IDH1 Mutation
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Leukemia
Vidaza Received New Indication for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Leukemia, Pediatric Cancer
Arsenic Trioxide–Induced QTc Interval Prolongation and the Potential Benefit of Beta-Blockers in Patients with Acute Promyelocytic Leukemia: Case Series
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in Case Reports, Leukemia, Adverse Events
Effect of Concomitant Azole Antifungals on Duration of Myelosuppression in Newly Diagnosed Patients with AML Receiving Venetoclax in Combination with Cladribine and Low-Dose Cytarabine
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Leukemia
Dasatinib-Induced Gynecomastia in 2 Patients with Chronic Myeloid Leukemia: Case Reports and Review of the Literature
Jessie Signorelli, PharmD, BCOP, Amir T. Fathi, MD, Gabriela Hobbs, MD
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in Case Reports, Leukemia, Adverse Events
Lidocaine plus Tetracaine–Medicated Patch Used for Propofol Sedation During Lumbar Punctures in Pediatric Patients with Blood Cancer
Lisa R. Garavaglia, PharmD , Frank Casey, MD, Lesley Cottrell, PhD, Claudiu Faraon-Pogaceanu, MD, Stephan Paul, MD, Melvin Lee Wright, DO
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in Original Article, Pediatric Cancer, Leukemia, Lymphoma
Myeloablative and Reduced-Intensity Preparative Regimens for Allogeneic Transplant in the Outpatient versus Inpatient Setting in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
Gretchen Pardo, PharmD, Beth Eddy, PharmD, BCOP, Zahra Mahmoudjafari, PharmD, BCOP, Dennis Grauer, PhD, MS, Joseph McGuirk, DO
JHOP - August 2021 Vol 11, No 4 published on August 17, 2021 in Original Article, Transplant, Leukemia, Myelodysplastic Syndromes, Conditioning Regimen
Pharmacy Resident–Led Medication Reconciliation and Patient Education Service in Adults with Leukemia Receiving Anticancer Oral Agents: A Pilot Study
Lily Y. Jia, PharmD, BCOP, Jessie Signorelli, PharmD, BCOP, Samantha O. Luk, PharmD, BCOP, E. Bridget Kim, PharmD, BCPS, BCOP, Gayle C. Blouin, PharmD, BCOP
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in Original Article, Leukemia, Oncology Pharmacy Programs
Pegaspargase-Induced Diabetic Ketoacidosis in a Patient with Acute Lymphoblastic Leukemia
Ellen Madarang, PharmD, BCOP, Leslie Gallardo, PharmD, BCPS, Terrence Bradley, MD
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in Case Reports, Acute Lymphoblastic Leukemia, Leukemia, Adverse Events
Oral Azacitidine Prolongs Survival in Patients with Acute Myeloid Leukemia
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in From the Literature, Leukemia
© Amplity Health. All rights reserved.